Dye developed in Pittsburgh could predict Alzheimer's 10 years before it strikes

An article published on August 11, 2008 in the Archives of Neurology suggests that a compound called "Pittsburgh Compound B" consistently attaches itself to proteins in the brain, and is 90% effective in predicting the later development of beta amyloid plaques, a leading cause of Alzheimer's Disease.  Pittsburgh Compound B, or PiB as it is commonly known, is a compound that was developed by University of Pittsburgh researchers as a way to diagnose Alzheimer's Disease.  Now, doctors in Finland have discovered that not only is PiB effective in diagnosing the disease once it develops, it also can be used to predict, 10 years in advance, if people are at higher risk of developing the disease.  For more information about Alzheimer's Disease, click here.

If you suspect that your disease process, whatever it may be, was not timely and properly diagnosed or treated, please call us directly at 412-471-4300 or 800-350-6161, or click here.  Berger & Lagnese, headquartered in Pittsburgh, specializes in medical malpractice and works on cases in Pittsburgh, Greensburg, Uniontown, Erie, Washington, and all courts in Western Pennsylvania.